Publication:
Cisplatin plus etoposide in the adjuvant treatment of patients with non small cell lung cancer

Research Projects

Organizational Units

Journal Issue

Abstract

Aim: In this study, the efficacy and safety of cisplatin and etoposide (PE) combination in the adjuvant treatment of patients with resected non-small cell lung cancer (NSCLC) was investigated. Material and Method: We retrospectively evaluated the medical charts of patients receiving adjuvant treatment for NSCLC at our center. Results: Forty-five patients were evaluated. The disease-free survival was 10 (1-114) months and the median overall survival was 18 (3-114) months. Discussion: Based on our limited experience, we concluded that PE regimen is safe and effective as adjuvant therapy for patients with NSCLC.

Description

Keywords

Nonsmall cell lung cancer, Adjuvant chemotherapy, Cisplatin, General & internal medicine

Citation

Collections


Metrikler

Search on Google Scholar


Total Views

3

Total Downloads

6